Immunomodulatory Properties of Recombinant Murine and Human Tumor Necrosis Factor

James E Talmadge, Hamblin Phillips, Mark Schneider, Tammy Rowe, Robin Pennington, Orville Bowersox, Barbara Lenz

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Tumor necrosis factor has traditionally been thought to have direct cytostatic and cytotoxic properties with little or no direct immunomodulatory activity. We report here that tumor necrosis factor is able to activate macrophages both in vitro and in vivo and can increase a mixed lymphocyte response and act as an adjuvant for both T- and B-cells in vivo. Adjuvant activity in T-cells occurred in conjunction with the administration of a suboptimal syngeneic tumor cell vaccine. In addition, tumor necrosis factor demonstrated a potent dose-dependent effect on bone marrow stem cell number, dramatically depressing cellularity and thus total stem cell number. An appreciable interval is required for recovery from such stem cell depletion. Therefore, the study of the therapeutic activity of tumor necrosis factor must include a consideration of its immunomodulatory properties.

Original languageEnglish (US)
Pages (from-to)584-588
Number of pages5
JournalCancer Research
Volume48
Issue number3
StatePublished - 1988
Externally publishedYes

Fingerprint

Tumor Necrosis Factor-alpha
Stem Cells
Cell Count
Cancer Vaccines
Cytostatic Agents
Bone Marrow Cells
B-Lymphocytes
Macrophages
Lymphocytes
T-Lymphocytes
human TNF protein
Therapeutics

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Talmadge, J. E., Phillips, H., Schneider, M., Rowe, T., Pennington, R., Bowersox, O., & Lenz, B. (1988). Immunomodulatory Properties of Recombinant Murine and Human Tumor Necrosis Factor. Cancer Research, 48(3), 584-588.

Immunomodulatory Properties of Recombinant Murine and Human Tumor Necrosis Factor. / Talmadge, James E; Phillips, Hamblin; Schneider, Mark; Rowe, Tammy; Pennington, Robin; Bowersox, Orville; Lenz, Barbara.

In: Cancer Research, Vol. 48, No. 3, 1988, p. 584-588.

Research output: Contribution to journalArticle

Talmadge, JE, Phillips, H, Schneider, M, Rowe, T, Pennington, R, Bowersox, O & Lenz, B 1988, 'Immunomodulatory Properties of Recombinant Murine and Human Tumor Necrosis Factor', Cancer Research, vol. 48, no. 3, pp. 584-588.
Talmadge JE, Phillips H, Schneider M, Rowe T, Pennington R, Bowersox O et al. Immunomodulatory Properties of Recombinant Murine and Human Tumor Necrosis Factor. Cancer Research. 1988;48(3):584-588.
Talmadge, James E ; Phillips, Hamblin ; Schneider, Mark ; Rowe, Tammy ; Pennington, Robin ; Bowersox, Orville ; Lenz, Barbara. / Immunomodulatory Properties of Recombinant Murine and Human Tumor Necrosis Factor. In: Cancer Research. 1988 ; Vol. 48, No. 3. pp. 584-588.
@article{918e31a669e6419892b863d0f5148263,
title = "Immunomodulatory Properties of Recombinant Murine and Human Tumor Necrosis Factor",
abstract = "Tumor necrosis factor has traditionally been thought to have direct cytostatic and cytotoxic properties with little or no direct immunomodulatory activity. We report here that tumor necrosis factor is able to activate macrophages both in vitro and in vivo and can increase a mixed lymphocyte response and act as an adjuvant for both T- and B-cells in vivo. Adjuvant activity in T-cells occurred in conjunction with the administration of a suboptimal syngeneic tumor cell vaccine. In addition, tumor necrosis factor demonstrated a potent dose-dependent effect on bone marrow stem cell number, dramatically depressing cellularity and thus total stem cell number. An appreciable interval is required for recovery from such stem cell depletion. Therefore, the study of the therapeutic activity of tumor necrosis factor must include a consideration of its immunomodulatory properties.",
author = "Talmadge, {James E} and Hamblin Phillips and Mark Schneider and Tammy Rowe and Robin Pennington and Orville Bowersox and Barbara Lenz",
year = "1988",
language = "English (US)",
volume = "48",
pages = "584--588",
journal = "Cancer Research",
issn = "0008-5472",
publisher = "American Association for Cancer Research Inc.",
number = "3",

}

TY - JOUR

T1 - Immunomodulatory Properties of Recombinant Murine and Human Tumor Necrosis Factor

AU - Talmadge, James E

AU - Phillips, Hamblin

AU - Schneider, Mark

AU - Rowe, Tammy

AU - Pennington, Robin

AU - Bowersox, Orville

AU - Lenz, Barbara

PY - 1988

Y1 - 1988

N2 - Tumor necrosis factor has traditionally been thought to have direct cytostatic and cytotoxic properties with little or no direct immunomodulatory activity. We report here that tumor necrosis factor is able to activate macrophages both in vitro and in vivo and can increase a mixed lymphocyte response and act as an adjuvant for both T- and B-cells in vivo. Adjuvant activity in T-cells occurred in conjunction with the administration of a suboptimal syngeneic tumor cell vaccine. In addition, tumor necrosis factor demonstrated a potent dose-dependent effect on bone marrow stem cell number, dramatically depressing cellularity and thus total stem cell number. An appreciable interval is required for recovery from such stem cell depletion. Therefore, the study of the therapeutic activity of tumor necrosis factor must include a consideration of its immunomodulatory properties.

AB - Tumor necrosis factor has traditionally been thought to have direct cytostatic and cytotoxic properties with little or no direct immunomodulatory activity. We report here that tumor necrosis factor is able to activate macrophages both in vitro and in vivo and can increase a mixed lymphocyte response and act as an adjuvant for both T- and B-cells in vivo. Adjuvant activity in T-cells occurred in conjunction with the administration of a suboptimal syngeneic tumor cell vaccine. In addition, tumor necrosis factor demonstrated a potent dose-dependent effect on bone marrow stem cell number, dramatically depressing cellularity and thus total stem cell number. An appreciable interval is required for recovery from such stem cell depletion. Therefore, the study of the therapeutic activity of tumor necrosis factor must include a consideration of its immunomodulatory properties.

UR - http://www.scopus.com/inward/record.url?scp=84965812123&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84965812123&partnerID=8YFLogxK

M3 - Article

VL - 48

SP - 584

EP - 588

JO - Cancer Research

JF - Cancer Research

SN - 0008-5472

IS - 3

ER -